# Sacituzumab Govitecan in Recurrent Glioblastoma

> **NCT04559230** · PHASE2 · RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 32 (estimated)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** Sacituzumab Govitecan

## Key facts

- **NCT ID:** NCT04559230
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-06
- **Primary completion:** 2027-02
- **Final completion:** 2028-02
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04559230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04559230, "Sacituzumab Govitecan in Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04559230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*